O-Demethylfortimicin A (compound A49759) was tested against 445 bacteria, and the results were compared with thooe obtained with fortimicin A, amikacin, gentamicin, netilmicin, sisomicin, and tobramycin. A49759 was found to be active and bactericidal against the Enterobacteriaceae, nonfermentative gram-negative bacilli, and Staphylococcus aureus. A49759 was two-to fourfold more active than fortimicin A against most species tested, but generally fourfold less active than amikacin against this population of Pseudomonas aeruginosa (85% inhibited at -16 ug of amikacin per ml and 85% inhibited at c64 ,ug of A49759 per ml). Only amikacin and A49759 were resistant to most aminoglycoside-inactivating enzymes and also had significant antipseudomonal activity. Amikacin was inactivated by aminoglycoside 6'-acetyltransferase, and A49759 was inactivated by aminoglycoside 3-acetyltransferase. The minimal inhibitory concentrations of all tested aminoglycosides were increased by augmenting the inoculum size. Several recent reports have described the in vitro antimicrobial activity of the pseudodisaccharide aminoglycoside antibiotics (4-8, 10, 11, 13, 14). Among these new compounds, the fortimicin group has been most extensively tested against recent clinical isolates (7). Numerous chemical and natural modifications of fortimicin have been presented (6, 8, 10, 14, 15) . Fortimicin aminoglycosides are generally resistant to inactivating enzymes (6, 10, 13), but lack significant inhibitory activity against pseudomonads (6, 7). In recently presented abstracts no ototoxicity and very low renal toxicity for fortimicin A in the animal models were described (C. 
Several recent reports have described the in vitro antimicrobial activity of the pseudodisaccharide aminoglycoside antibiotics (4-8, 10, 11, 13, 14) . Among these new compounds, the fortimicin group has been most extensively tested against recent clinical isolates (7). Numerous chemical and natural modifications of fortimicin have been presented (6, 8, 10, 14, 15) . Fortimicin aminoglycosides are generally resistant to inactivating enzymes (6, 10, 13) , but lack significant inhibitory activity against pseudomonads (6, 7) . In recently presented abstracts no ototoxicity and very low renal toxicity for fortimicin A in the animal models were described (C. Morganella sp., Providencia sp., and Serratia marcescens, the fortimicin A compounds and amikacin were more active than other aminoglycosides against these bacteria. Amikacin, fortimicin A, and A49759 are resistant to most inactivating enzymes except 6'-N-acetyltransferase [AAC(6')] for amikacin and 3-N-acetyltransferase-I [AAC(3)-I] for fortimicin A and A49759 (5, 12, 13) . Netilmicin was also very active against the Serratia isolates. (Table 3) . Only two isolates (P. aeruginosa and P. vulgaris) had A49759 MLCs 4-fold or greater than the MIC; 93 to 97% of aminoglycoside MLCs were s2-fold greater than the MIC. All of the higher netilmicin MLC/MIC ratios were with S. marcescens strains. * The effect of increasing inoculum concentrations on the MIC 90 is shown in Table 4 . Small MIC increases were found with all drugs when the inoculum density was raised from 103 to 105 CFU/ml. When a 107-CFU/ml inoculum was used, A49759 and the other aminoglycoside showed a variable MIC response ranging from no change to a 16-fold MIC increase as compared with MICs with an inoculum of 105 CFU/ml. A49759 MICs against P. aeruginosa and S. aureus were least affected by increasing the inoculum concentration. (5) . Due to the lower A49759 activity against P. aeruginosa, the extent of susceptibility to AAC(3)-I could not be accurately determined. Previous reports using AAC(3)-I-producing Enterobacteriaceae revealed significant inactivation of the pseudodisaccharide aminoglycosides (13 MIC studies using the same Mueller-Hinton broth lot without divalent cation supplement demonstrated four-to eightfold lower A49759 MIC values against P. aeruginosa only. All other aminoglycosides showed similar MIC shifts.
DISCUSSION
Abbott compound A49759, a derivative of fortimicin A, possesses in vitro antimicrobial activity superior to that described previously for fortimicin aminoglycosides (6-8, 10, 14, 15) . Its increased activity against P. aeruginosa compared with that of fortimicin A also seems superior to those recently described for sannamycin A, sporaricin A, and istamycin B (3, 4, 11) . A49759 was very active against the Enterobacteriaceae, other pseudomonads, acinetobacters, and the staphylococci. Streptococci, especially Streptococcus faecalis, were not significantly inhibited by the tested aminoglycosides.
The pseudodisaccharide aminocycitols are generally resistant to most bacteria-mediated (3, 4, 11, (13) (14) (15) . Only the AAC(3)-I enzyme (3-N-acetylation) routinely inactivates this series of drugs, as well as gentamicin, netilmicin, and sisomicin. Only amikacin and tobramycin among the currently available aminoglycosides were active against these isolates in vitro (3, 5, 12) . Conversely, the AAC(6') enzymes (6'-N-acetylation) will not inactivate A49759 or fortimicin A, but they confer resistance against most other aminoglycosides, including amikacin and netilmicin. None of the drugs tested was effective against the cell wall permeability mutants at <16 ,ug/ml.
The divalent cation content of the test broth exerts a profound effect on some A49759 MICs. The MIC increase offour-to eightfold associated with raising cation concentrations was similar to that described for other aminoglycosides tested against P. aeruginosa (2, 5; manuscript in preparation). Increasing inoculum also increased A49759 MICs, especially at 107 CFU/ml. A49759 had 97% of MLCs within fourfold of the MIC result, a finding comparable to that of gentamicin, sisomicin, and tobramycin.
We conclude that A49759 is a very active new pseudodisaccharide aminoglycoside having inhibitory and killing effects on a wide variety of bacteria. The superiority of A49759 to the related compound fortimicin A and its potential for lower in vivo toxicity support continued in vitro and in vivo investigations.
